High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• The Lancet. Lung cancer: some progress, but still a lot more to do. The Lancet. 2019;394(10212):1880 doi:10.1016/S0140-6736(19)32795-3.
   Web of Science ®Google Scholar
• Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 2017;7:193.
   PubMed Web of Science ®Google Scholar
• Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2011;32(4):703–740.
   PubMed Web of Science ®Google Scholar
• Ding K, Yi M, Li L, et al. Interleukin polymorphisms and protein levels associated with lung cancer susceptibility and phenotypes. Expert Rev Clin Immunol. 2021;17(9):1029–1040.
   PubMed Web of Science ®Google Scholar
• Saettele TM, Ost DE. Multimodality systematic approach to mediastinal lymph node staging in non-small cell lung cancer. Respirology. 2014;19(6):800–808.
   PubMed Web of Science ®Google Scholar
• Fischer BM, Mortensen J, Hansen H, et al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax. 2011;66(4):294–300.
   PubMed Web of Science ®Google Scholar
• Knight SB, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.
   PubMed Web of Science ®Google Scholar
• Xie X, Wang L, Wang X, et al. Evaluation of cell surface vimentin positive circulating tumor cells as a diagnostic biomarker for lung cancer. Front Oncol. 2021;11:672687.
   PubMed Web of Science ®Google Scholar
• Jin X, Chen Y, Chen H, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017;23(17):5311–5319.
   PubMed Web of Science ®Google Scholar
• Xu L, Yi M, Tan Y, et al. A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma. Ther Adv Respir Dis. 2020;14:1753466620981863.
   Web of Science ®Google Scholar
• Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 2016;76(13):3666–3670.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Calin GA, Lopez-Berestein G, et al. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6(3):235–246.
   PubMed Web of Science ®Google Scholar
• Thind A, Wilson C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. J Extracell Vesicles. 2016;5:31292.
   PubMed Web of Science ®Google Scholar
• Inamura K, Ishikawa Y. MicroRNA in lung cancer: Novel biomarkers and potential tools for treatment. JCM. 2016;5(3):36.
   Web of Science ®Google Scholar
• Bica-Pop C, Cojocneanu-Petric R, Magdo L, et al. Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75(19):3539–3551.
   PubMed Web of Science ®Google Scholar
• Chen Y, Min L, Ren C, et al. miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. PLOS One. 2017;12(2):e0171751.
   PubMed Web of Science ®Google Scholar
• Kim DH, Park S, Kim H, et al. Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4. Cancer Lett. 2020;475:2–13.
   PubMed Web of Science ®Google Scholar
• Jiang L-P, Zhu Z-T, He C-Y. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer. Future Oncol. 2016;12(9):1105–1115.
   PubMed Web of Science ®Google Scholar
• Khandelwal A, Seam RK, Gupta M, et al. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer. Cancer Sci. 2020;111(3):826–839.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Groome PA, Bolejack V, Crowley JJ, Participating Institutions, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Chansky K, Groome P, IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, et al. The IASLC lung cancer staging project: Methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11(9):1433–1446.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, WHO Panel, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E. Muller-Hermelink Hk Pathology and genetics: tumours of the lung, pleura, thymus and heart: World health organization. Classification of tumours. Lyon:IARC Press. 2004.
   Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, QUADAS-2 Group, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536.
   PubMed Web of Science ®Google Scholar
• Spearman's rank correlation coefficient. BMJ. 2018;362:k4131.
   PubMedGoogle Scholar
• Reitsma JB, Glas AS, Rutjes AWS, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982–990.
   PubMed Web of Science ®Google Scholar
• Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148–1157.
   PubMed Web of Science ®Google Scholar
• Biljana M, Jelena M, Branislav J, et al. Bias in meta-analysis and funnel plot asymmetry. Stud Health Technol Inform. 1999;68:323–328.
   PubMedGoogle Scholar
• Jennions MD, Møller AP. Publication bias in ecology and evolution: an empirical assessment using the 'trim and fill' method. Biol Rev. 2002;77(2):211–222.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tang Y, Song X, et al. Tumor-derived exosomal mirnas as diagnostic biomarkers in non-small cell lung cancer. Front Oncol. 2020;10. doi:10.3389/fonc.2020.560025.
   Web of Science ®Google Scholar
• Yang C, Jia X, Zhou J, et al. The mir-17-92 gene cluster is a blood-based marker for cancer detection in non-small-cell lung cancer. Am J Med Sci. 2020;360(3):248–260. doi:10.1016/j.amjms.2020.05.004. 32466856
   PubMed Web of Science ®Google Scholar
• Wu Q, Yu L, Lin X, et al. Combination of Serum miRNAs with Serum Exosomal miRNAs in Early Diagnosis for Non-Small-Cell Lung Cancer. CMAR. 2020;ume 12:485–495. doi:10.2147/CMAR.S232383.
   Google Scholar
• Wang W, Chen D, Chen W, et al. Early detection of Non-Small cell lung cancer by using a 12-microRNA panel and a nomogram for assistant diagnosis. Front Oncol. 2020;10:855.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang C, Peng X, et al. A combination of four serum mirnas for screening of lung adenocarcinoma. Hum Cell. 2020;33(3):830–838. doi:10.1007/s13577-020-00346-6. 32388809
   PubMed Web of Science ®Google Scholar
• Liu X, Tang C, Song X, et al. Clinical value of CTLA4-associated micrornas combined with inflammatory factors in the diagnosis of non-small cell lung cancer. Ann Clin Biochem. 2020;57(2):151–161. doi:10.1177/0004563220901564. 31906699
   PubMed Web of Science ®Google Scholar
• Liu C, Kannisto E, Yu G, et al. Non-invasive detection of exosomal MicroRNAs via tethered cationic lipoplex nanoparticles (tCLN) biochip for lung cancer early detection. Front Genet. 2020;11:258.
   PubMed Web of Science ®Google Scholar
• Liao J, Shen J, Leng Q, et al. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC). Thorac Cancer. 2020;11(3):762–768. doi:10.1111/1759-7714.13337. 31994346
   PubMed Web of Science ®Google Scholar
• Ghany S, Ali E, Ahmed AE, et al. Circulating mirna-30a and mirna-221 AS novel biomarkers for the early detection of non-small-cell lung cancer. Middle East Journal of Cancer. 2020;11(1):50–58.
   Web of Science ®Google Scholar
• Fehlmann T, Kahraman M, Ludwig N, et al. Evaluating the use of circulating microrna profiles for lung cancer detection in symptomatic patients. JAMA Oncol. 2020;6(5):714–723. doi:10.1001/jamaoncol.2020.0001. 32134442
   PubMed Web of Science ®Google Scholar
• Asakura K, Kadota T, Matsuzaki J, et al. A mirna-based diagnostic model predicts resectable lung cancer in humans with high accuracy. Commun Biol. 2020;3(1):134 doi:10.1038/s42003-020-0863-y. PMC: 32193503
   PubMed Web of Science ®Google Scholar
• Zou J-G, Ma L-F, Li X, et al. Circulating microrna array (miR-182, 200b and 205) FOR THE early diagnosis and poor prognosis predictor of non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2019;23(3):1108–1115. doi:10.26355/eurrev_201902_17001. 30779079
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Yin Y, et al. Detection of circulating exosomal mir-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients. Pathology- Research and Practice. 2019;215(8):152466 doi:10.1016/j.prp.2019.152466.
   PubMed Web of Science ®Google Scholar
• Xi K, Wang W, Wen Y, et al. Combining plasma mirnas and computed tomography features to differentiate the nature of pulmonary nodules. Front Oncol. 2019;9:975 doi:10.3389/fonc.2019.00975. PMC: 31632908
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Z, Wang Q, et al. Clinical significance of the expression of mirna-21, mirna-31 AND mirna-let7 in patients with lung cancer. Saudi J Biol Sci. 2019;26(4):777–781. doi:10.1016/j.sjbs.2018.12.009. 31049003
   PubMed Web of Science ®Google Scholar
• Szczyrek M, Kuźnar-Kamińska B, Grenda A, et al. Diagnostic value of plasma expression of micrornas complementary to drosha and dicer in lung cancer patients. Eur Rev Med Pharmacol Sci. 2019;23(9):3857–3866. doi:10.26355/eurrev_201905_17813. 31115013
   PubMed Web of Science ®Google Scholar
• Świtlik WZ, Karbownik MS, Suwalski M, et al. Serum mir-210-3p as a potential noninvasive biomarker of lung adenocarcinoma: A preliminary study. Genet Test Mol Biomarkers. 2019;23(5):353–358. doi:10.1089/gtmb.2018.0275. 30950648
   PubMed Web of Science ®Google Scholar
• Sui A, Zhang X, Zhu Q. Diagnostic value of serum miR197 and miR145 in non-small cell lung cancer. Oncol Lett. 2019;doi:10.3892/ol.2019.9958.
   Web of Science ®Google Scholar
• Sheervalilou R, Lotfi H, Shirvaliloo M, et al. Circulating mir-10b, mir-1 AND mir-30a expression profiles in lung cancer: Possible correlation with clinico-pathologic characteristics and lung cancer detection. Int J Mol Cell Med. 2019;8(2):118–129. doi:10.22088/IJMCM.BUMS.8.2.118. 32215263
   PubMed Web of Science ®Google Scholar
• Roman-Canal B, Moiola CP, Gatius S, et al. EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer. Sci Rep. 2019;9(1):15057.
   PubMed Web of Science ®Google Scholar
• Li J, Fang H, Jiang F, et al. External validation of a panel of plasma microrna biomarkers for lung cancer. Biomark Med. 2019;13(18):1557–1564. doi:10.2217/bmm-2019-0213. 31674214
   PubMed Web of Science ®Google Scholar
• Hetta HF, Zahran AM, El-Mahdy RI, et al. Assessment of circulating mirna-17 AND mirna-222 expression profiles as non-invasive biomarkers in egyptian patients with non-small-cell lung cancer. Asian Pac J Cancer Prev. 2019;20(6):1927–1933. doi:10.31557/APJCP.2019.20.6.1927. 31244320
   PubMedGoogle Scholar
• Abdollahi A, Rahmati S, Ghaderi B, et al. A combined panel of circulating microrna as a diagnostic tool for detection of the non-small cell lung cancer. QJM. 2019;112(10):779–785. doi:10.1093/qjmed/hcz158. 31236600
   PubMed Web of Science ®Google Scholar
• Yang YL, Wang W, Xu LP. Predictive value of microrna-10b expression in peripheral blood mononuclear cells in evaluating short- AND long-term efficacy of chemotherapy for patients with advanced non-small-cell lung cancer. Neoplasma. 2018;65(4):610–619. doi:10.4149/neo_2018_170110N20. 30064233
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen K, Zhou Y, et al. Application of serum microrna-9-5p, 21-5p, and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China. Onco Targets Ther. 2018;11:587–597. doi:10.2147/OTT.S152957. 29430184
   PubMed Web of Science ®Google Scholar
• Xi KX, Zhang XW, Yu XY, et al. The role of plasma miRNAs in the diagnosis of pulmonary nodules. J Thorac Dis. 2018;10(7):4032–4041.
   PubMed Web of Science ®Google Scholar
• Sun Y, Mei H, Xu C, et al. Circulating microrna-339-5p and-21 in plasma as an early detection predictors of lung adenocarcinoma. Pathol Res Pract. 2018;214(1):119–125. doi:10.1016/j.prp.2017.10.011. 29103767
   PubMed Web of Science ®Google Scholar
• Qiu F, Gu WG, Li C, et al. Analysis on expression level and diagnostic value of mir-19 AND mir-21 in peripheral blood of patients with undifferentiated lung cancer. Eur Rev Med Pharmacol Sci. 2018;22(23):8367–8373.
   PubMed Web of Science ®Google Scholar
• Poroyko V, Mirzapoiazova T, Nam A, et al. Exosomal mirnas species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 2018;9(28):19793–19806. doi:10.18632/oncotarget.24857. 29731983
   PubMedGoogle Scholar
• Mohamed MA, Mohamed EI, El-Kaream SAA, et al. Underexpression of mir-486-5p but not overexpression of mir-155 is associated with lung cancer stages. MIRNA. 7(2):120–127. doi:10.2174/2211536607666180212124532.
   Google Scholar
• Leng Q, Wang Y, Jiang F. A direct plasma mirna assay for early detection and histological classification of lung cancer. Transl Oncol. 2018;11(4):883–889. doi:10.1016/j.tranon.2018.05.001. 29783093
   PubMed Web of Science ®Google Scholar
• Fan LH, Chen H, Teng JL, et al. Evaluation of Serum-Paired miRNA ratios for early diagnosis of Non-Small cell lung cancer using quantum Dot-Based suspension array. J Nanomater. 2018;2018:1–9.
   Web of Science ®Google Scholar
• Bao M, Pan S, Yang W, et al. Serum mir-10a-5p and mir-196a-5p as non-invasive biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2018;11(2):773–780.
   PubMed Web of Science ®Google Scholar
• Bagheri A, Khorshid HRK, Tavallaie M, et al. A panel of noncoding rnas in non-small-cell lung cancer. J Cell Biochem. 2018;doi:10.1002/jcb.28111. 30485511
   Google Scholar
• Aiso T, Ohtsuka K, Ueda M, et al. Serum levels of candidate microRNA diagnostic markers differ among the stages of non-small-cell lung cancer. Oncol Lett. 2018;16(5):6643–6651.
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Javid J, Sughayer MA, et al. Clinical significance of circulatory mirna-21 AS AN efficient non-invasive biomarker for the screening of lung cancer patients. Asian Pacific Journal of Cancer Prevention : APJCP. 2018;19(9):2607–2611.
   PubMedGoogle Scholar
• Zhang H, Mao F, Shen T, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett. 2017;13(2):669–676.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zuo J, Tan Q, et al. Plasma mir-92a-2 AS A biomarker for small cell lung cancer. CBM. 18(3):319–327. doi:10.3233/CBM-160254.
   Google Scholar
• Sheervalilou R, Khamaneh AM, Sharifi A, et al. Using miR-10b, miR-1 and miR-30a expression profiles of bronchoalveolar lavage and sputum for early detection of non-small cell lung cancer. Biomedicine and Pharmacotherapy. 2017;88:1173–1182.
   Web of Science ®Google Scholar
• Shang AQ, Xie YN, Wang J, et al. Predicative values of serum microrna-22 AND microrna-126 levels for non-small cell lung cancer development and metastasis: A case-control study. Neoplasma. 2017;64(3):453–459. doi:10.4149/neo_2017_317. 28253725
   PubMed Web of Science ®Google Scholar
• Lv S, Xue J, Wu C, et al. Identification of a panel of serum micrornas as biomarkers for early detection of lung adenocarcinoma. J Cancer. 2017;8(1):48–56. doi:10.7150/jca.16644. 28123597
   PubMed Web of Science ®Google Scholar
• Leng Q, Lin Y, Jiang F, et al. A plasma mirna signature for lung cancer early detection. Oncotarget. 2017;8(67):111902–111911. doi:10.18632/oncotarget.22950.
   PubMedGoogle Scholar
• Ibrahim FK, Ali-Labib R, Galal IH, et al. MicroRNA-155 expression in exhaled breath condensate of patients with lung cancer. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66(4):687–691.
   Web of Science ®Google Scholar
• Bagheri A, Khorram Khorshid HR, Mowla SJ, et al. Altered mir-223 expression in sputum for diagnosis of non-small cell lung cancer. Avicenna J Med Biotechnol. 2017;9(4):189–195.
   PubMedGoogle Scholar
• Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum mir-182, mir-183, mir-210, and mir-126 levels in patients with early-stage non-small cell lung cancer. PLoS One. 2016;11(4):e0153046 doi:10.1371/journal.pone.0153046. PMC: 27093275
   PubMed Web of Science ®Google Scholar
• Zaporozhchenko IA, Morozkin ES, Skvortsova TE, et al. Plasma mir-19b and mir-183 AS potential biomarkers of lung cancer. PLoS One. 2016;11(10):e0165261 doi:10.1371/journal.pone.0165261. PMC: 27768748
   PubMed Web of Science ®Google Scholar
• Wang X, Zhi X, Zhang Y, et al. Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study. J Thorac Dis. 2016;8(7):1645–1652.
   PubMed Web of Science ®Google Scholar
• Su Y, Fang H, Jiang F. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection. Clin Epigenetics. 2016;8:109.
   Google Scholar
• Su Y, Fang H, Jiang F. Integrating DNA methylation and microrna biomarkers in sputum for lung cancer detection. Clin Epigenet. 2016;8(1)doi:10.1186/s13148-016-0275-5.
   Google Scholar
• Razzak R, Bédard ELR, Kim JO, et al. MicroRNA expression profiling of sputum for the detection of early and locally advanced non-small-cell lung cancer: A prospective case-control study. Curr Oncol. 2016;23(2):e86–e94. doi:10.3747/co.23.2830. 27122989
   PubMed Web of Science ®Google Scholar
• Jia Y, Zang A, Feng Y, et al. miRNA-486 AND mirna-499 in human plasma evaluate the clinical stages of lung cancer and play a role as a tumor suppressor in lung tumorigeneisis not pathogenesis. Bangladesh J Pharmacol. 2016;11(1):264. doi:10.3329/bjp.v11i1.25318.
   Web of Science ®Google Scholar
• Chen JL, Chen JR, Han HN, Zhou F, Lv XD, Ma H. Clinical significance of miRNA21 in exhaled breath condensate of non-small-cell lung cancer. International J Clin Exp. 2016;9(9):17232–8.
   Google Scholar
• Zhao W, Zhao JJ, Zhang L, et al. Serum mir-21 level: A potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Med. 2015;8(9):14759–14763.
   PubMed Web of Science ®Google Scholar
• Yang J-S, Li B-J, Lu H-W, et al. Serum mir-152, mir-148a, mir-148b, and mir-21 AS novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36(4):3035–3042. doi:10.1007/s13277-014-2938-1. 25501703
   PubMedGoogle Scholar
• Yan HJ, Ma JY, Wang L, Gu W. Expression and significance of circulating microRNA-31 in lung cancer patients. Med Sci Monit. 2015;21:722–6.
   Google Scholar
• Xing L, Su J, Guarnera MA, et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res. 2015;21(2):484–489.
   PubMed Web of Science ®Google Scholar
• Wang RJ, Zheng YH, Wang P, Zhang JZ. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(1):765–71.
   Google Scholar
• Wang P, Yang D, Zhang H, et al. Early detection of lung cancer in serum by a panel of microrna biomarkers. Clin Lung Cancer. 2015;16(4):313–319.e1. doi:10.1016/j.cllc.2014.12.006. 25639977
   PubMed Web of Science ®Google Scholar
• Su J, Anjuman N, Guarnera MA, et al. Analysis of lung flute-collected sputum for lung cancer diagnosis. Biomark Insights. 2015;10:55–61. doi:10.4137/BMI.S26883. 26309391
   PubMedGoogle Scholar
• Li W, Wang Y, Zhang Q, et al. MicroRNA-486 AS A biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One. 2015;10(8):e0134220 doi:10.1371/journal.pone.0134220. PMC: 26237047
   PubMed Web of Science ®Google Scholar
• Fan L, Qi H, Teng J, et al. Identification of serum mirnas by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer. Tumor Biol. 2016;37(6):7777–7784. doi:10.1007/s13277-015-4608-3.
   PubMedGoogle Scholar
• Dou H, Wang Y, Su G, et al. Decreased plasma let-7c and mir-152 AS noninvasive biomarker for non-small-cell lung cancer. Int J Clin Exp Med. 2015;8(6):9291–9298.
   PubMed Web of Science ®Google Scholar
• Zhu W-Y, Luo B, An J-Y, et al. Differential expression of mir-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest. 2014;32(8):394–401. doi:10.3109/07357907.2014.922569. 24945821
   PubMed Web of Science ®Google Scholar
• Li N, Ma J, Guarnera MA, et al. Digital PCR quantification of mirnas in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140(1):145–150. doi:10.1007/s00432-013-1555-5. 24281335
   PubMed Web of Science ®Google Scholar
• Geng Q, Fan T, Zhang B, et al. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Respir Res. 2014;15:149.
   PubMed Web of Science ®Google Scholar
• Zeng XL, Zhang SY, Zheng JF, et al. Altered mir-143 AND mir-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer. Chin Med J (Engl). 2013;126(23):4510–4516.
   PubMed Web of Science ®Google Scholar
• Tang D, Shen Y, Wang M, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22(6):540–548.
   PubMed Web of Science ®Google Scholar
• Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 2013;18(8):679–686.
   PubMed Web of Science ®Google Scholar
• Anjuman N, Li N, Guarnera M, et al. Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. Clinical and Translational Medicine. 2013;2(1). doi:10.1186/2001-1326-2-15.
   PubMedGoogle Scholar
• Abd-El-Fattah AA, Sadik NAH, Shaker OG, et al. Differential micrornas expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013;67(3):875–884. doi:10.1007/s12013-013-9575-y. 23559272
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang Q. The expression and clinical significance of circulating microrna-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138(10):1659–1666. doi:10.1007/s00432-012-1244-9.
   PubMed Web of Science ®Google Scholar
• Wei J, Liu L-K, Gao W, et al. Reduction of plasma microrna-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin J Cancer Res. 2011;23(2):123–128. doi:10.1007/s11670-011-0123-2.
   PubMed Web of Science ®Google Scholar
• Wei J, Gao W, Zhu C-J, et al. Identification of plasma microrna-21 AS A biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011;30(6):407–414. doi:10.5732/cjc.010.10522.
   PubMedGoogle Scholar
• Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91(4):579–587.
   PubMed Web of Science ®Google Scholar
• Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microrna biomarkers. BMC Cancer. 2011;11:374 doi:10.1186/1471-2407-11-374. PMC: 21864403
   PubMed Web of Science ®Google Scholar
• Li Y, Li W, Ouyang Q, et al. Detection of lung cancer with blood microrna-21 expression levels in chinese population. Oncol Lett. 2011;2(5):991–994. doi:10.3892/ol.2011.351. 22866162
   PubMed Web of Science ®Google Scholar
• Jeong HC, Kim EK, Lee JH, et al. Aberrant expression of let-7a mirna in the blood of non-small cell lung cancer patients. Mol Med Rep. 2011;4(2):383–387. doi:10.3892/mmr.2011.430. 21468581
   PubMed Web of Science ®Google Scholar
• Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2010;127(12):2870–2878.
   PubMed Web of Science ®Google Scholar
• Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microrna markers. Mod Pathol. 2010;23(8):1157–1164. doi:10.1038/modpathol.2010.111. 20526284
   PubMed Web of Science ®Google Scholar
• Xie Y, Todd NW, Liu Z, et al. Altered mirna expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67(2):170–176. doi:10.1016/j.lungcan.2009.04.004.
   PubMed Web of Science ®Google Scholar
• Zhong S, Golpon H, Zardo P, et al. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res. 2021;230:164–196.
   PubMed Web of Science ®Google Scholar
• Borzi C, Ganzinelli M, Caiola E, et al. LKB1 down-modulation by miR-17 identifies NSCLC patients with worse prognosis eligible for energy-stress based treatments. J Thor Oncol. 2021;16(8):1298–1311.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fu W, Liao H, Dai L, Jiang Z, Pan Y, et al. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer. Bmc Cancer. 2015;15.
   Google Scholar
• Wang H, Chen J, Zhang S, et al. MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer. Cancer Cell Int. 2020;20(1)
   Web of Science ®Google Scholar
• Ahn Y-H, Ko YH. Diagnostic and therapeutic implications of microRNAs in non-small cell lung cancer. IJMS. 2020;21(22):8782.
   Web of Science ®Google Scholar
• Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534(1):60–65.
   PubMed Web of Science ®Google Scholar
• Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108(9):3713–3718.
   PubMed Web of Science ®Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. doi:10.1126/scitranslmed.aan2415. 28814544
   Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• Lu Q, Shan S, Li Y, et al. Long noncoding RNA SNHG1 promotes non-small cell lung cancer progression by up-regulating MTDH via sponging miR-145-5p. Faseb J. 2018;32(7):3957–3967.
   PubMed Web of Science ®Google Scholar
• Mataki H, Seki N, Mizuno K, et al. Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. Oncotarget. 2016;7(44):72084–72098.
   PubMedGoogle Scholar
• Wang J, Tian X, Han R, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2014;33(9):1181–1189.
   PubMed Web of Science ®Google Scholar
• Borzi C, Calzolari L, Centonze G, et al. Mir-660-p53-mir-486 network: a new key regulatory pathway in lung tumorigenesis. IJMS. 2017;18(1):222.
   Web of Science ®Google Scholar
• Laurie W, Szaloky LG. Sputum cytology in the diagnosis of bronchial carcinoma. Med J Aust. 1971;1(5):247–251.
   PubMed Web of Science ®Google Scholar
• Oswald NC, Hinson KF, Canti G, et al. The diagnosis of primary lung cancer with special reference to sputum cytology. Thorax. 1971;26(6):623–627.
   PubMed Web of Science ®Google Scholar
• Arai T, Yasuda Y, Takaya T, et al. Application of telomerase activity for screening of primary lung cancer in broncho-alveolar lavage fluid. Oncol Rep. 1998;5(2):405–408.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao W, Zhang L, et al. MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via WNT signaling pathway. Oncotarget. 2017;8(55):94317–94329.
   PubMedGoogle Scholar
• Chen Z, Xu Z, Sun S, et al. TGF-beta 1, IL-6, and TNF-alpha in bronchoalveolar lavage fluid: useful markers for lung cancer? Sci Rep. 2014;4:5595.
   PubMed Web of Science ®Google Scholar
• Chan HP, Lewis C, Thomas PS. Exhaled breath analysis: novel approach for early detection of lung cancer. Lung Cancer. 2009;63(2):164–168.
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
   PubMed Web of Science ®Google Scholar
• Madhavan B, Yue S, Galli U, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136(11):2616–2627.
   PubMed Web of Science ®Google Scholar
• de Abreu FB, Liu X, Tsongalis GJ. miRNA analysis in pancreatic cancer: the dartmouth experience. Clin Chem Lab Med. 2017;55(5):755–762.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhu D, Wu L, et al. Six Serum-Based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(2):188–196.
   PubMed Web of Science ®Google Scholar
• Usuba W, Urabe F, Yamamoto Y, et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 2019;110(1):408–419.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liu J, Quan J, et al. MicroRNAs as potential biomarkers for the diagnosis of glioma: a systematic review and meta-analysis. Cancer Sci. 2018;109(9):2651–2659.
   PubMed Web of Science ®Google Scholar
• Li Y, Li M, Zhang Y, et al. Age-stratified and gender-specific reference intervals of six tumor markers panel of lung cancer: a geographic-based multicenter study in China. J Clin Lab Anal. 2021;35(6):e23816–e.
   PubMed Web of Science ®Google Scholar
• Passaro A, Attili I, Rappa A, et al. Genomic characterization of concurrent alterations in non-small cell lung cancer (NSCLC) harboring actionable mutations. Cancers. 2021;13(9):2172.
   PubMed Web of Science ®Google Scholar
• Shao J, Lyu W, Zhou J, et al. A panel of five-lncRNA signature as a potential biomarker for predicting survival in gastric and thoracic cancers. Front Genet. 2021;12:666155.
   PubMed Web of Science ®Google Scholar